<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00307255</url>
  </required_header>
  <id_info>
    <org_study_id>LCCC 0520</org_study_id>
    <secondary_id>CDR0000550136</secondary_id>
    <nct_id>NCT00307255</nct_id>
  </id_info>
  <brief_title>Paclitaxel Albumin-Stabilized Nanoparticle Formulation and Gemcitabine in Treating Patients With Advanced Metastatic Solid Tumors</brief_title>
  <official_title>Phase I Trial of Abraxane in Combination With Gemcitabine in Patients With Solid Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>UNC Lineberger Comprehensive Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>UNC Lineberger Comprehensive Cancer Center</source>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy, such as paclitaxel albumin-stabilized nanoparticle&#xD;
      formulation and gemcitabine, work in different ways to stop the growth of tumor cells, either&#xD;
      by killing the cells or by stopping them from dividing. Giving more than one drug&#xD;
      (combination chemotherapy) may kill more tumor cells.&#xD;
&#xD;
      PURPOSE: This phase I trial is studying the side effects and best dose of paclitaxel&#xD;
      albumin-stabilized nanoparticle formulation when given together with gemcitabine in treating&#xD;
      patients with advanced metastatic solid tumors.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
      Primary&#xD;
&#xD;
        -  Determine the dose-limiting toxicity and maximum tolerated dose of paclitaxel&#xD;
           albumin-stabilized nanoparticle formulation (Abraxane) in combination with gemcitabine&#xD;
           hydrochloride in patients with advanced metastatic solid tumors.&#xD;
&#xD;
      Secondary&#xD;
&#xD;
        -  Evaluate the efficacy of this regimen in these patients.&#xD;
&#xD;
      OUTLINE: This is a dose-escalation study of paclitaxel albumin-stabilized nanoparticle&#xD;
      formulation (Abraxane).&#xD;
&#xD;
      Patients receive paclitaxel albumin-stabilized nanoparticle formulation (Abraxane) IV over 30&#xD;
      minutes on day 1 followed by gemcitabine hydrochloride IV over 30 minutes on days 1 and 8.&#xD;
      Treatment repeats every 21 days for up to 6 courses in the absence of disease progression or&#xD;
      unacceptable toxicity.&#xD;
&#xD;
      Cohorts of 3-6 patients receive escalating doses of paclitaxel albumin-stabilized&#xD;
      nanoparticle formulation (Abraxane) until the maximum tolerated dose (MTD) is determined. The&#xD;
      MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience&#xD;
      dose-limiting toxicity. Up to 10 additional patients may be treated at the MTD.&#xD;
&#xD;
      After completion of study treatment, patients are followed at 30 days.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2006</start_date>
  <completion_date type="Actual">October 2008</completion_date>
  <primary_completion_date type="Actual">September 2007</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Dose Limiting Toxicity (DLT)</measure>
    <time_frame>21 days</time_frame>
    <description>Toxicity will be graded using the CTCAE version 3.0 and will be assessed on cycle one (21 days)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum Tolerated Dose(MTD)</measure>
    <time_frame>1 year</time_frame>
    <description>If greater than or equal to 2 of 6 patients (33%) experience a DLT, then that dose level will be considered to have excessive toxicity and will = MTD</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Radiographic Response to Treatment</measure>
    <time_frame>every 42 days</time_frame>
    <description>Radiographic response will be measured and evaluated using RECIST criteria.</description>
  </secondary_outcome>
  <enrollment type="Actual">18</enrollment>
  <condition>Unspecified Adult Solid Tumor, Protocol Specific</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>gemcitabine hydrochloride</intervention_name>
    <description>1000 mg/m2 on days 1 and 8 of each 21 day cycle</description>
    <other_name>Gemzar</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>paclitaxel albumin-stabilized nanoparticle formulation</intervention_name>
    <description>260 mg/m2 to 340 mg/m2 (dose will depend on when subject enters the study). Paclitaxel will be given on day 1 of each 21 day cycle (every 3 weeks)</description>
    <other_name>Abraxane</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically or cytologically confirmed solid tumors&#xD;
&#xD;
               -  Advanced metastatic disease&#xD;
&#xD;
          -  Measurable or evaluable disease&#xD;
&#xD;
          -  Must meet 1 of the following criteria:&#xD;
&#xD;
               -  Failed prior standard therapy&#xD;
&#xD;
               -  Not a candidate for standard therapy&#xD;
&#xD;
               -  Has a disease for which there is no defined standard therapy&#xD;
&#xD;
          -  No symptomatic brain metastases&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
          -  ECOG functional status 0-2&#xD;
&#xD;
          -  Life expectancy ≥ 8 weeks&#xD;
&#xD;
          -  Absolute neutrophil count ≥ 1,500/mm^3&#xD;
&#xD;
          -  Platelet count &gt; 100,000/mm^3&#xD;
&#xD;
          -  Hemoglobin ≥ 9.0 g/dL&#xD;
&#xD;
          -  Bilirubin normal&#xD;
&#xD;
          -  Creatinine ≤ 1.5 times upper limit of normal (ULN) OR creatinine clearance ≥ 60 mL/min&#xD;
&#xD;
          -  AST and ALT ≤ 2.5 times ULN&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  No prior anaphylactic reaction or severe allergic reaction to paclitaxel, docetaxel,&#xD;
             or gemcitabine hydrochloride&#xD;
&#xD;
          -  No active infectious process that will require treatment with antibiotics for &gt; 4&#xD;
             weeks&#xD;
&#xD;
          -  No uncontrolled congestive heart failure&#xD;
&#xD;
          -  No symptomatic coronary artery disease or heart block&#xD;
&#xD;
          -  No myocardial infarction within the past 3 months&#xD;
&#xD;
          -  No peripheral neuropathy ≥ grade 2 from any cause&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
          -  More than 3 weeks since prior chemotherapy, radiotherapy, or any other treatment&#xD;
&#xD;
          -  No prior radiotherapy to &gt; 25% of bone marrow&#xD;
&#xD;
          -  No prior nitrosoureas&#xD;
&#xD;
          -  No more than 6 prior courses of alkylating agents&#xD;
&#xD;
          -  No more than 2 prior courses of mitomycin C&#xD;
&#xD;
          -  No more than 3 prior courses of cytotoxic therapy for metastatic disease&#xD;
&#xD;
          -  No concurrent filgrastim (G-CSF), pegfilgrastim, or sargramostim (GM-CSF) during study&#xD;
             course 1&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Thomas E. Stinchcombe, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>UNC Lineberger Comprehensive Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of North Carolina Lineberger Comprehensive Cancer Center</name>
      <address>
        <city>Chapel Hill</city>
        <state>North Carolina</state>
        <zip>27599</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2012</verification_date>
  <study_first_submitted>March 24, 2006</study_first_submitted>
  <study_first_submitted_qc>March 24, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 27, 2006</study_first_posted>
  <last_update_submitted>April 2, 2012</last_update_submitted>
  <last_update_submitted_qc>April 2, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 4, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>unspecified adult solid tumor</keyword>
  <keyword>protocol specific</keyword>
  <keyword>Paclitaxel</keyword>
  <keyword>Abraxane</keyword>
  <keyword>Gemcitabine</keyword>
  <keyword>Gemzar</keyword>
  <keyword>Phase I</keyword>
  <keyword>Lineberger</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gemcitabine</mesh_term>
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Albumin-Bound Paclitaxel</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

